Targeted markets Small team focused on non-invasive drug delivery to inner ear, middle ear, and eye, presenting a niche capability for partnerships with ophthalmology and otology players seeking non-surgical delivery options.

Non-invasive edge Proprietary magnetic injection system enables delivery without puncturing the eardrum, potentially appealing to clinics and research institutions prioritizing patient comfort and reduced procedural risk.

Clinical readiness Preclinical evidence shows potential for tinnitus, noise-induced hearing loss, chemotherapy-induced hearing loss mitigation, creating opportunity for collaborations with pharma companies developing niche indications.

Funding signals Recent and historical non-dilutive and high-net-worth investor funding combined with NIH/NCI SBIR activity indicates investor interest and potential for grant-assisted partnerships.

Strategic partnerships University spin-out with technology transferable to hearing and ocular therapies; potential for co-development, licensing, or sponsored programs with larger pharma, biotech, or contract R&D firms seeking innovative delivery platforms.